Welcome to our dedicated page for Enovis SEC filings (Ticker: ENOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enovis Corporation (NYSE: ENOV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Enovis describes itself as an innovation-driven medical technology growth company with two primary segments, Prevention & Recovery (P&R) and Reconstructive (Recon), and its filings offer detailed insight into how this orthopedic-focused business reports its financial condition, capital structure and governance matters.
Investors can review Form 8-K filings where Enovis reports material events, such as quarterly earnings releases, changes in senior leadership roles, amendments to its credit agreement and other significant corporate developments. For example, recent 8-Ks have covered second- and third-quarter financial results, a retirement transition for a senior human resources executive, and an amendment to the company’s credit agreement that adjusts maturity dates, leverage ratio thresholds and borrowing terms.
Beyond current reports, Enovis’ annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via EDGAR) typically contain segment information for Prevention & Recovery and Reconstructive, discussions of non-GAAP measures such as adjusted EBITDA and adjusted net income, and risk factor disclosures that may reference acquisitions and integration, including the acquisition of Lima. These filings help explain how the company evaluates its performance and manages its medical technology portfolio.
Stock Titan enhances access to Enovis filings by pairing real-time updates from EDGAR with AI-powered summaries that explain the key points in plain language. Users can quickly understand what a new 8-K, 10-Q or 10-K means for Enovis’ operations, capital structure or governance without reading every page. The platform also makes it easier to track items such as credit agreement amendments and other direct financial obligations that Enovis reports under the SEC’s requirements.
Enovis Corporation (ENOV) filed a Form 4 disclosing an insider withholding transaction by reporting person John Kleckner, identified as the company's Principal Accounting Officer. On 08/05/2025, 173 shares of Enovis common stock were withheld in connection with the net settlement of restricted stock units to satisfy tax withholding obligations at a per‑share amount of $26.46. The filing explicitly notes this action does not represent a sale by the reporting person.
After the withholding, Mr. Kleckner beneficially owned 9,834 shares of Enovis common stock, held directly. The Form 4 was signed by attorney‑in‑fact Brian P. Hanigan on 08/07/2025. The filing includes the reporting person’s address in Wilmington, DE.
Ross Terry D, Group President, P&R, of Enovis Corporation (ENOV) reported a Form 4 transaction dated 08/05/2025. The filing shows 325 common shares were withheld by the company to satisfy tax withholding in connection with the net settlement of restricted stock units, at a per-share price of $26.46. Following this withholding, the reporting person is shown as beneficially owning 35,789 shares. The form was filed by one reporting person and signed by attorney-in-fact Brian P. Hanigan on 08/07/2025.
The filing explicitly states the withheld shares do not represent a sale by the reporting person.
Enovis (ENOV) Q2 2025 10-Q highlights: Net sales grew 7.5% YoY to $564.5 million, led by Reconstructive (+10.7%) and steady Prevention & Recovery (+4.6%). Gross profit rose 15.9% to $334.7 million, lifting gross margin to 59.3% (vs. 55.0%). Operating loss narrowed to $16.8 million from $44.2 million on flat SG&A, but a $10.0 million royalty-buyout charge, higher R&D and intangible amortization kept GAAP earnings negative.
The company reported a net loss attributable to Enovis of $36.7 million (-$0.64 per share) versus $18.6 million (-$0.34) last year, driven by a $10.8 million tax expense versus an $8.9 million benefit in the prior period and hedging losses. Adjusted EBITDA improved 7.7% to $97.1 million. Operating cash flow swung to an inflow of $46.2 million (-$28.4 million LY) as working-capital efficiencies offset higher inventory. Cash ended at $44.1 million; total debt increased to $1.39 billion, lifting net debt by $84 million since year-end.
Balance-sheet expansion reflects completion of seven small acquisitions ($35 million consideration) and Lima integration costs. Inventories climbed 15% YTD, while goodwill and intangibles rose after bolt-on deals. Management remains in compliance with leverage covenants (senior secured leverage ≤3.5×) and has $325 million undrawn on its $900 million revolver.
Enovis Corporation (ENOV) filed a Form 8-K on 7 Aug 2025 to furnish Item 2.02 information. The filing states that a press release detailing Q2 FY25 results (quarter ended 4 Jul 2025) was issued the same day and is included as Exhibit 99.1. Management will host a conference call at 8:30 a.m. ET on 7 Aug 2025 to discuss those results. No financial figures, guidance, or qualitative commentary are provided within the 8-K itself. Exhibit 104 indicates the cover page is formatted in Inline XBRL.
The 8-K therefore serves solely as a procedural furnishing of the earnings release and does not, on its own, reveal performance metrics or forward-looking statements.